President Itai Nemovicher said OIC, which develops products in areas including trauma, spine and sports medicine, aims to accomplish this savings by producing implants which cost 50-60 percent of the average market cost of premium implants, according to the release.
OIC was formed as a collaboration between practicing orthopedic surgeons, hospital administration and orthopedic industry insiders, led by Mr. Nemovicher and Timothy Bray, MD, orthopedic traumatologist and a director of the company’s board.
“As a surgeon dedicated to the care of orthopedic trauma patients, I am pleased that OIC will help provide quality outcomes in a cost-effective manner,” said Dr. Bray in the news release. “In this period of global cost containment we believe our business model is well positioned for the future of orthopedic trauma. We are committed to cost-effective, comparative research and working with hospitals and insurers to deliver a national, reproducible program.”
Read the news release about the market entry for Orthopaedic Implant Company.
Learn more about Orthopaedic Implant Company.
Related Articles on Implants:
FDA Orders Additional Studies From Device Companies on Hip Implants
